Zymeworks Inc (NAS:ZYME)
$ 14.5 0 (0%) Market Cap: 998.72 Mil Enterprise Value: 721.77 Mil PE Ratio: 0 PB Ratio: 2.75 GF Score: 73/100

Zymeworks Inc at Citi BioPharma Conference Transcript

Sep 06, 2023 / 02:30PM GMT
Release Date Price: $7.2 (-1.77%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Great. The next panel is ADC antibody drug conjugates. I'm Yigal Nochomovitz. I'm one of the biotech analysts here. I cover all 3 of these companies, MacroGenics, Zai Lab and Zymeworks. So Scott Koenig, CEO of MacroGenics, welcome; Rafael Amado, President, Head of Global Oncology and R&D at Zai Lab; and Paul Moore, CSO at Zymeworks. So thank you all very much for being here. I appreciate it.

Just to start out, why don't we just do a quick lightning around. Give us a very quick introduction to the company and then with a specific focus on your ADC programs and just some of the very key highlights and then we can go from there.

Scott Koenig
MacroGenics, Inc. - President, CEO & Director

Terrific. Scott Koenig. So MacroGenics is 23 years in operation. We've been focused on developing immune-based therapeutics from the inception. We have 3 validated proprietary platforms, Fc-engineered molecules, bispecifics, which we call DART molecules and then ADC program. The company has been

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot